Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

Pfizer Inc. (NYSE:PFE) stock is trading higher with a session volume of 31.16 million as per data from Benzinga Pro. Activist ...

RSV vaccine sales from GSK and Pfizer have dropped significantly following revised CDC guidelines, narrowing the eligible age ...

In another positive development, Pfizer won a bid in a London court to invalidate two of GSK Plc’s (NYSE:GSK) patents relating to its respiratory syncytial virus (RSV) vaccine. Also Read ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus ...

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...